Association of antioxidant supplement use and dementia in the prevention of Alzheimer's disease by Vitamin E and selenium trial (PREADViSE)

JAMA Neurology

Volumn 74, Issue 5, 2017, Pages 567-573

  Kryscio, Richard J ^a,b   Abner, Erin L ^a,b   Caban Holt, Allison ^a,b   Lovell, Mark ^a,b   Goodman, Phyllis ^c   Darke, Amy K ^c   Yee, Monica ^c   Crowley, John ^c   Schmitt, Frederick A ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; PLACEBO; SELENIUM; ANTIOXIDANT;

AGED; ALZHEIMER DISEASE; ARTICLE; BLACK PERSON; CHEMOPROPHYLAXIS; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMORBIDITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG USE; EDUCATIONAL STATUS; HISPANIC; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; DEMENTIA; DIETARY SUPPLEMENT; LONGITUDINAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT;

AGED; ALZHEIMER DISEASE; ANTIOXIDANTS; DEMENTIA; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SELENIUM; VITAMIN E;

EID: 85016163044     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.5778     Document Type: Article

References (40)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3 (3):186-191.
2. Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275(3):251-283.
3. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014;13(8): 788-794.
4. Solomon A, Mangialasche F, Richard E, et al. Advances in the prevention of Alzheimer's disease and dementia. J Intern Med. 2014;275(3):229-250.
5. Kivipelto M, Solomon A, Ahtiluoto S, et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimers Dement. 2013;9(6):657-665.
6. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-2263.
7. Kryscio RJ. Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point. JAMA Neurol. 2014;71(8): 947-949.
8. Ogen-Shtern N, Ben David T, Lederkremer GZ. Protein aggregation and ER stress. Brain Res. 2016; 1648(pt B):658-666.
9. Rinaldi P, Polidori MC, Metastasio A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging. 2003;24(7):915-919.
10. Viña J, Lloret A, Ortí R, Alonso D. Molecular bases of the treatment of Alzheimer's disease with antioxidants: prevention of oxidative stress. Mol Aspects Med. 2004;25(1-2):117-123.
11. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N Engl JMed. 1997;336(17):1216-1222.
12. Galasko DR, Peskind E, Clark CM, et al; Alzheimer's Disease Cooperative Study. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012;69(7):836-841.
13. Petersen RC, Thomas RG, Grundman M, et al; Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23): 2379-2388.
14. Loef M, Schrauzer GN, Walach H. Selenium and Alzheimer's disease: a systematic review. J Alzheimers Dis. 2011;26(1):81-104.
15. Arnaud J, Akbaraly TN, Hininger I, Roussel AM, Berr C. Factors associated with longitudinal plasma selenium decline in the elderly: the EVA study [published correction appears in J Nutr Biochem. 2008;19(4):275]. J Nutr Biochem. 2007;18(7):482-487.
16. Gao S, Jin Y, Hall KS, et al. Selenium level and cognitive function in rural elderly Chinese. Am J Epidemiol. 2007;165(8):955-965.
17. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301 (1):39-51.
18. Kryscio RJ, Abner EL, Schmitt FA, et al; SELECT Investigators. A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. J Nutr Health Aging. 2013;17(1):72-75.
19. Kryscio RJ, Mendiondo MS, Schmitt FA, MarkesberyWR. Designing a large prevention trial: statistical issues. Stat Med. 2004;23(2):285-296.
20. Goodman PJ, Hartline JA, Tangen CM, et al. Moving a randomized clinical trial into an observational cohort. Clin Trials. 2013;10(1):131-142.
21. Buschke H, Kuslansky G, Katz M, et al. Screening for dementia with the memory impairment screen. Neurology. 1999;52(2):231-238.
22. de Jager CA, Budge MM, Clarke R. Utility of TICS-M for the assessment of cognitive function in older adults. Int J Geriatr Psychiatry. 2003;18(4): 318-324.
23. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part I: clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39(9):1159-1165.
24. Mathews M, Abner E, Caban-Holt A, Kryscio R, Schmitt F. CERAD practice effects and attrition bias in a dementia prevention trial. Int Psychogeriatr. 2013;25(7):1115-1123.
25. Galvin JE, Roe CM, Powlishta KK, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65(4):559-564.
26. Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol. 1999;12(4):168-179.
27. DeKosky ST, Williamson JD, Fitzpatrick AL, et al; Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300(19):2253-2262.
28. Lyketsos CG, Breitner JC, Green RC, et al; ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68(21):1800-1808.
29. Coker LH, Espeland MA, Rapp SR, et al. Postmenopausal hormone therapy and cognitive outcomes: theWomen's Health Initiative Memory Study (WHIMS). J Steroid Biochem Mol Biol. 2010; 118(4-5):304-310.
30. Vellas B, Coley N, Ousset PJ, et al; GuidAge Study Group. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11(10): 851-859.
31. Vinceti M, Mandrioli J, Borella P, Michalke B, Tsatsakis A, Finkelstein Y. Selenium neurotoxicity in humans: bridging laboratory and epidemiologic studies. Toxicol Lett. 2014;230(2):295-303.
32. Yang GQ, Wang SZ, Zhou RH, Sun SZ. Endemic selenium intoxication of humans in China. Am J Clin Nutr. 1983;37(5):872-881.
33. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005; 142(1):37-46.
34. Abner EL, Schmitt FA, Mendiondo MS, Marcum JL, Kryscio RJ. Vitamin E and all-cause mortality: ameta-analysis. Curr Aging Sci. 2011;4(2):158-170.
35. Fowler NR, Frame A, Perkins AJ, et al. Traits of patients who screen positive for dementia and refuse diagnostic assessment. Alzheimers Dement (Amst). 2015;1(2):236-241.
36. Storandt M, Morris JC. Ascertainment bias in the clinical diagnosis of Alzheimer disease. Arch Neurol. 2010;67(11):1364-1369.
37. Galvin JE, Roe CM, Coats MA, Morris JC. Patient's rating of cognitive ability: using the AD8, a brief informant interview, as a self-rating tool to detect dementia. Arch Neurol. 2007;64(5):725-730.
38. Monteiro IM, Boksay I, Auer SR, Torossian C, Sinaiko E, Reisberg B. Reliability of routine clinical instruments for the assessment of Alzheimer's disease administered by telephone. J Geriatr Psychiatry Neurol. 1998;11(1):18-24.
39. Duff K, Beglinger LJ, Adams WH. Validation of the modified telephone interview for cognitive status in amnestic mild cognitive impairment and intact elders. Alzheimer Dis Assoc Disord. 2009;23 (1):38-43.
40. Lovell MA, Xiong S, Lyubartseva G, Markesbery WR. Organoselenium (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 mice. Free Radic Biol Med. 2009;46(11):1527-1533.